期刊文献+

水痘带状疱疹病毒培养液的筛选

Screening of medium for varicella-zoster virus
原文传递
导出
摘要 目的筛选培养水痘带状疱疹病毒(varicella-zoster virus,VZV)的培养液。方法将4种不同的培养基分别与新生牛血清、人血白蛋白组合,配制12组不同的病毒培养液,培养VZV后,采用噬斑法检测病毒滴度。用筛选出的病毒培养液,对VZV进行6个40层细胞工厂的扩大化培养及连续传代培养,收获P1和P5病毒,进行ORF62核酸序列测序,利用DNAMan软件对测序结果进行比对分析。结果实验2、4、11组培养液培养的VZV滴度明显高于其他组(P均<0.05),选择实验4组培养液对VZV进行扩大化培养后,病毒滴度均稳定在约5.4 Lg PFU/ml;连续传代培养,ORF62核酸序列无碱基突变。结论筛选出1种不含血清及人血白蛋白的VZV培养液,可以稳定地培养VZV。 Objective To screen the culture medium for varicella-zoster virus(VZV). Methods Twelve groups of virus culture media were formulated with four kinds of media and newborn bovine serum or human serum albumin, with which VZV was cultured and determined for titer. By using the screened medium, VZV was subjected to expand culture and continuous subculture in six 40-layer cell factory. The VZV of P1 and P5 were harvested, of which the ORF62 was sequenced, and the result was analyzed by using DNAMan software. Results The titers of VZV in media of groups 2, 4 and 11 were significantly higher than those in other groups(each P 〈 0. 05). The medium of group 4 was screened for expand culture, in which the VZV titer was stabilized at about 5. 4 Lg PFU/ml. No base mutation was found in the nucleic acid sequence of ORF62 of VZV after continuous subculture. Conclusion A serum-and human serum albumin-free medium was screened, which was suitable for stable culture of VZV.
出处 《中国生物制品学杂志》 CAS CSCD 2017年第11期1128-1130,共3页 Chinese Journal of Biologicals
关键词 水痘带状疱疹病毒 培养基 细胞工厂 筛选 核酸序列 Varicella-zoster virus (VZV) Medium cell factory Screening nucleic acid sequence
  • 相关文献

参考文献3

二级参考文献18

  • 1庞成华,彭佩霞,刘小琳,王桂秋,陈秀珍,王用楫.北京株水痘活疫苗的研制[J].中国生物制品学杂志,1994,7(4):156-158. 被引量:6
  • 2周铁群,陈震,王剑锋,英志芳,邱平,范行良,李娟,李长贵,方捍华,陈海平,李秀玲,谢芸,许丽锋,郭绍红,董春明,刘立新,罗耀兴,蔡汉港,张吉凯,徐宁,张铭驱,李建基.我国自行研制的冻干水痘减毒活疫苗的临床效果评价[J].中国生物制品学杂志,2005,18(4):342-345. 被引量:20
  • 3TAKAHASHI M. Current status and prospects of live varicella vaccine[J]. Vaccine, 1992, 10(14): 1007-1014.
  • 4ARVIN AM. Varicella-zoster virus [ J ]. Clin Microbiol Rev, 1996, 9(3): 361 -381.
  • 5SHEFFER R, SEGAL D, RAHAMANI S, et al. Effectiveness of the Oka/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel[J]. Pediatr Infect Dis J,2005, 24(5): 434 -437.
  • 6HAMBLETON S, GERSI-ION AA. Preventing varicella-zoster disease[J]. Clin Microbiol Rev, 2005, 18 ( 1 ) : 70 - 80.
  • 7WHO. TRS requirement for varicella vaccine (live) [ S]. 1994: 222 - 381.
  • 8VILLANI S, MARAZZI M, BUCCO M, et al. Statistical approach in alginate membrane formulation for cell encapsulation in a GMP-based cell factory [ J ]. Acta Biomaterialia, 2008, 4 (4) : 943 - 949.
  • 9HAGEN AJ, ABOUD RA, DEPHILLIPS PA, et al. Use of a nu- clease enzyme in the purification of VAQTA, a hepatitis A vac- cine[J]. Biotechnol Appl Biochem, 1996, 23(3) : 209 -215.
  • 10Schmid DS,Jumaan AO.Impact of varicella vaccine on varicellazoster virus dynamics[J].Clin Microbiol Rev,2010,23(1):202-217.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部